Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen
Summary 202 patients with acute leukemia (156 myeloid-AML, 46 lymphatic and undifferentiated-ALL/AUL) were studied retrospectively for the efficiency of different treatment schedules. Other variables we analysed were the influence of infection prevention with reverse isolation in laminar air flow un...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Deutsch |
| Erschienen: |
1983 |
|---|
| Umfang: |
10 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Journal of molecular medicine - 1922, 61(1983) vom: Juli, Seite 329-338 |
| Übergeordnetes Werk: |
volume:61 ; year:1983 ; month:07 ; pages:329-338 ; extent:10 |
| Links: |
|---|
| Katalog-ID: |
NLEJ199367191 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ199367191 | ||
| 003 | DE-627 | ||
| 005 | 20230506103810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070527s1983 xx |||||o 00| ||ger c | ||
| 035 | |a (DE-627)NLEJ199367191 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 245 | 1 | 0 | |a Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen |
| 264 | 1 | |c 1983 | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary 202 patients with acute leukemia (156 myeloid-AML, 46 lymphatic and undifferentiated-ALL/AUL) were studied retrospectively for the efficiency of different treatment schedules. Other variables we analysed were the influence of infection prevention with reverse isolation in laminar air flow units and of the age as a prognostic factor. 34% of all AML-patients achieved complete remission. Therapy with Adriamycin, Cytosine-Arabinoside and Vincristine resulted in 25 complete remissions in 51 patients (49%). The median duration of remission was 8 months and the median survival 19 months. The remission rate was improved by treatment with Cytosine-Arabinoside, 6-Thioguanine and Daunomycin (11 of 17 patients). Remission rate was significantly higher in patients up to 30 years of age than in patients older than 50 years (p<0.008). Survival and remission duration were not different in respect to the age. Reverse isolation with total enteral and topical decontamination resulted in a higher remission rate (p=0.06 not significant) in AML-patients, compared with the control-group. Survival lasted longer with infection prevention. In ALL/AUL-patients the rate of complete remissions was 16 of 34 patients (47%), with a median survival of 17 months. Patients up to the age of 30 had a higher remission rate than those older than 50 years (p=0.017). Patients with ALL/AUL younger than 31 years had a median duration of remission of 16 months and a survival probability of 0.66 after 43 months. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Link, H. |4 oth | |
| 700 | 1 | |a Frauer, H. M. |4 oth | |
| 700 | 1 | |a Wilms, K. |4 oth | |
| 700 | 1 | |a Waller, H. D. |4 oth | |
| 773 | 0 | 8 | |i in |t Journal of molecular medicine |d 1922 |g 61(1983) vom: Juli, Seite 329-338 |w (DE-627)NLEJ188988254 |w (DE-600)1462132-0 |x 1432-1440 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:1983 |g month:07 |g pages:329-338 |g extent:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF01485023 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 1983 |c 7 |h 329-338 |g 10 | ||
| matchkey_str |
article:14321440:1983----::adleteaiegbisbiktrekiutrnednvrcidnreadugshmtmteodrrecsc |
|---|---|
| hierarchy_sort_str |
1983 |
| publishDate |
1983 |
| allfields |
(DE-627)NLEJ199367191 DE-627 ger DE-627 rakwb ger Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen 1983 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary 202 patients with acute leukemia (156 myeloid-AML, 46 lymphatic and undifferentiated-ALL/AUL) were studied retrospectively for the efficiency of different treatment schedules. Other variables we analysed were the influence of infection prevention with reverse isolation in laminar air flow units and of the age as a prognostic factor. 34% of all AML-patients achieved complete remission. Therapy with Adriamycin, Cytosine-Arabinoside and Vincristine resulted in 25 complete remissions in 51 patients (49%). The median duration of remission was 8 months and the median survival 19 months. The remission rate was improved by treatment with Cytosine-Arabinoside, 6-Thioguanine and Daunomycin (11 of 17 patients). Remission rate was significantly higher in patients up to 30 years of age than in patients older than 50 years (p<0.008). Survival and remission duration were not different in respect to the age. Reverse isolation with total enteral and topical decontamination resulted in a higher remission rate (p=0.06 not significant) in AML-patients, compared with the control-group. Survival lasted longer with infection prevention. In ALL/AUL-patients the rate of complete remissions was 16 of 34 patients (47%), with a median survival of 17 months. Patients up to the age of 30 had a higher remission rate than those older than 50 years (p=0.017). Patients with ALL/AUL younger than 31 years had a median duration of remission of 16 months and a survival probability of 0.66 after 43 months. Springer Online Journal Archives 1860-2002 Link, H. oth Frauer, H. M. oth Wilms, K. oth Waller, H. D. oth in Journal of molecular medicine 1922 61(1983) vom: Juli, Seite 329-338 (DE-627)NLEJ188988254 (DE-600)1462132-0 1432-1440 nnns volume:61 year:1983 month:07 pages:329-338 extent:10 http://dx.doi.org/10.1007/BF01485023 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 61 1983 7 329-338 10 |
| spelling |
(DE-627)NLEJ199367191 DE-627 ger DE-627 rakwb ger Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen 1983 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary 202 patients with acute leukemia (156 myeloid-AML, 46 lymphatic and undifferentiated-ALL/AUL) were studied retrospectively for the efficiency of different treatment schedules. Other variables we analysed were the influence of infection prevention with reverse isolation in laminar air flow units and of the age as a prognostic factor. 34% of all AML-patients achieved complete remission. Therapy with Adriamycin, Cytosine-Arabinoside and Vincristine resulted in 25 complete remissions in 51 patients (49%). The median duration of remission was 8 months and the median survival 19 months. The remission rate was improved by treatment with Cytosine-Arabinoside, 6-Thioguanine and Daunomycin (11 of 17 patients). Remission rate was significantly higher in patients up to 30 years of age than in patients older than 50 years (p<0.008). Survival and remission duration were not different in respect to the age. Reverse isolation with total enteral and topical decontamination resulted in a higher remission rate (p=0.06 not significant) in AML-patients, compared with the control-group. Survival lasted longer with infection prevention. In ALL/AUL-patients the rate of complete remissions was 16 of 34 patients (47%), with a median survival of 17 months. Patients up to the age of 30 had a higher remission rate than those older than 50 years (p=0.017). Patients with ALL/AUL younger than 31 years had a median duration of remission of 16 months and a survival probability of 0.66 after 43 months. Springer Online Journal Archives 1860-2002 Link, H. oth Frauer, H. M. oth Wilms, K. oth Waller, H. D. oth in Journal of molecular medicine 1922 61(1983) vom: Juli, Seite 329-338 (DE-627)NLEJ188988254 (DE-600)1462132-0 1432-1440 nnns volume:61 year:1983 month:07 pages:329-338 extent:10 http://dx.doi.org/10.1007/BF01485023 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 61 1983 7 329-338 10 |
| allfields_unstemmed |
(DE-627)NLEJ199367191 DE-627 ger DE-627 rakwb ger Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen 1983 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary 202 patients with acute leukemia (156 myeloid-AML, 46 lymphatic and undifferentiated-ALL/AUL) were studied retrospectively for the efficiency of different treatment schedules. Other variables we analysed were the influence of infection prevention with reverse isolation in laminar air flow units and of the age as a prognostic factor. 34% of all AML-patients achieved complete remission. Therapy with Adriamycin, Cytosine-Arabinoside and Vincristine resulted in 25 complete remissions in 51 patients (49%). The median duration of remission was 8 months and the median survival 19 months. The remission rate was improved by treatment with Cytosine-Arabinoside, 6-Thioguanine and Daunomycin (11 of 17 patients). Remission rate was significantly higher in patients up to 30 years of age than in patients older than 50 years (p<0.008). Survival and remission duration were not different in respect to the age. Reverse isolation with total enteral and topical decontamination resulted in a higher remission rate (p=0.06 not significant) in AML-patients, compared with the control-group. Survival lasted longer with infection prevention. In ALL/AUL-patients the rate of complete remissions was 16 of 34 patients (47%), with a median survival of 17 months. Patients up to the age of 30 had a higher remission rate than those older than 50 years (p=0.017). Patients with ALL/AUL younger than 31 years had a median duration of remission of 16 months and a survival probability of 0.66 after 43 months. Springer Online Journal Archives 1860-2002 Link, H. oth Frauer, H. M. oth Wilms, K. oth Waller, H. D. oth in Journal of molecular medicine 1922 61(1983) vom: Juli, Seite 329-338 (DE-627)NLEJ188988254 (DE-600)1462132-0 1432-1440 nnns volume:61 year:1983 month:07 pages:329-338 extent:10 http://dx.doi.org/10.1007/BF01485023 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 61 1983 7 329-338 10 |
| allfieldsGer |
(DE-627)NLEJ199367191 DE-627 ger DE-627 rakwb ger Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen 1983 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary 202 patients with acute leukemia (156 myeloid-AML, 46 lymphatic and undifferentiated-ALL/AUL) were studied retrospectively for the efficiency of different treatment schedules. Other variables we analysed were the influence of infection prevention with reverse isolation in laminar air flow units and of the age as a prognostic factor. 34% of all AML-patients achieved complete remission. Therapy with Adriamycin, Cytosine-Arabinoside and Vincristine resulted in 25 complete remissions in 51 patients (49%). The median duration of remission was 8 months and the median survival 19 months. The remission rate was improved by treatment with Cytosine-Arabinoside, 6-Thioguanine and Daunomycin (11 of 17 patients). Remission rate was significantly higher in patients up to 30 years of age than in patients older than 50 years (p<0.008). Survival and remission duration were not different in respect to the age. Reverse isolation with total enteral and topical decontamination resulted in a higher remission rate (p=0.06 not significant) in AML-patients, compared with the control-group. Survival lasted longer with infection prevention. In ALL/AUL-patients the rate of complete remissions was 16 of 34 patients (47%), with a median survival of 17 months. Patients up to the age of 30 had a higher remission rate than those older than 50 years (p=0.017). Patients with ALL/AUL younger than 31 years had a median duration of remission of 16 months and a survival probability of 0.66 after 43 months. Springer Online Journal Archives 1860-2002 Link, H. oth Frauer, H. M. oth Wilms, K. oth Waller, H. D. oth in Journal of molecular medicine 1922 61(1983) vom: Juli, Seite 329-338 (DE-627)NLEJ188988254 (DE-600)1462132-0 1432-1440 nnns volume:61 year:1983 month:07 pages:329-338 extent:10 http://dx.doi.org/10.1007/BF01485023 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 61 1983 7 329-338 10 |
| allfieldsSound |
(DE-627)NLEJ199367191 DE-627 ger DE-627 rakwb ger Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen 1983 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary 202 patients with acute leukemia (156 myeloid-AML, 46 lymphatic and undifferentiated-ALL/AUL) were studied retrospectively for the efficiency of different treatment schedules. Other variables we analysed were the influence of infection prevention with reverse isolation in laminar air flow units and of the age as a prognostic factor. 34% of all AML-patients achieved complete remission. Therapy with Adriamycin, Cytosine-Arabinoside and Vincristine resulted in 25 complete remissions in 51 patients (49%). The median duration of remission was 8 months and the median survival 19 months. The remission rate was improved by treatment with Cytosine-Arabinoside, 6-Thioguanine and Daunomycin (11 of 17 patients). Remission rate was significantly higher in patients up to 30 years of age than in patients older than 50 years (p<0.008). Survival and remission duration were not different in respect to the age. Reverse isolation with total enteral and topical decontamination resulted in a higher remission rate (p=0.06 not significant) in AML-patients, compared with the control-group. Survival lasted longer with infection prevention. In ALL/AUL-patients the rate of complete remissions was 16 of 34 patients (47%), with a median survival of 17 months. Patients up to the age of 30 had a higher remission rate than those older than 50 years (p=0.017). Patients with ALL/AUL younger than 31 years had a median duration of remission of 16 months and a survival probability of 0.66 after 43 months. Springer Online Journal Archives 1860-2002 Link, H. oth Frauer, H. M. oth Wilms, K. oth Waller, H. D. oth in Journal of molecular medicine 1922 61(1983) vom: Juli, Seite 329-338 (DE-627)NLEJ188988254 (DE-600)1462132-0 1432-1440 nnns volume:61 year:1983 month:07 pages:329-338 extent:10 http://dx.doi.org/10.1007/BF01485023 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 61 1983 7 329-338 10 |
| language |
German |
| source |
in Journal of molecular medicine 61(1983) vom: Juli, Seite 329-338 volume:61 year:1983 month:07 pages:329-338 extent:10 |
| sourceStr |
in Journal of molecular medicine 61(1983) vom: Juli, Seite 329-338 volume:61 year:1983 month:07 pages:329-338 extent:10 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Journal of molecular medicine |
| authorswithroles_txt_mv |
Link, H. @@oth@@ Frauer, H. M. @@oth@@ Wilms, K. @@oth@@ Waller, H. D. @@oth@@ |
| publishDateDaySort_date |
1983-07-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188988254 |
| id |
NLEJ199367191 |
| language_de |
deutsch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ199367191</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506103810.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1983 xx |||||o 00| ||ger c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ199367191</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1983</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary 202 patients with acute leukemia (156 myeloid-AML, 46 lymphatic and undifferentiated-ALL/AUL) were studied retrospectively for the efficiency of different treatment schedules. Other variables we analysed were the influence of infection prevention with reverse isolation in laminar air flow units and of the age as a prognostic factor. 34% of all AML-patients achieved complete remission. Therapy with Adriamycin, Cytosine-Arabinoside and Vincristine resulted in 25 complete remissions in 51 patients (49%). The median duration of remission was 8 months and the median survival 19 months. The remission rate was improved by treatment with Cytosine-Arabinoside, 6-Thioguanine and Daunomycin (11 of 17 patients). Remission rate was significantly higher in patients up to 30 years of age than in patients older than 50 years (p<0.008). Survival and remission duration were not different in respect to the age. Reverse isolation with total enteral and topical decontamination resulted in a higher remission rate (p=0.06 not significant) in AML-patients, compared with the control-group. Survival lasted longer with infection prevention. In ALL/AUL-patients the rate of complete remissions was 16 of 34 patients (47%), with a median survival of 17 months. Patients up to the age of 30 had a higher remission rate than those older than 50 years (p=0.017). Patients with ALL/AUL younger than 31 years had a median duration of remission of 16 months and a survival probability of 0.66 after 43 months.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Link, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Frauer, H. M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilms, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Waller, H. D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Journal of molecular medicine</subfield><subfield code="d">1922</subfield><subfield code="g">61(1983) vom: Juli, Seite 329-338</subfield><subfield code="w">(DE-627)NLEJ188988254</subfield><subfield code="w">(DE-600)1462132-0</subfield><subfield code="x">1432-1440</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:61</subfield><subfield code="g">year:1983</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:329-338</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01485023</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">61</subfield><subfield code="j">1983</subfield><subfield code="c">7</subfield><subfield code="h">329-338</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188988254 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-1440 |
| topic_title |
Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
h l hl h m f hm hmf k w kw h d w hd hdw |
| hierarchy_parent_title |
Journal of molecular medicine |
| hierarchy_parent_id |
NLEJ188988254 |
| hierarchy_top_title |
Journal of molecular medicine |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188988254 (DE-600)1462132-0 |
| title |
Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen |
| spellingShingle |
Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen |
| ctrlnum |
(DE-627)NLEJ199367191 |
| title_full |
Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen |
| journal |
Journal of molecular medicine |
| journalStr |
Journal of molecular medicine |
| lang_code |
ger |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1983 |
| contenttype_str_mv |
zzz |
| container_start_page |
329 |
| container_volume |
61 |
| physical |
10 |
| format_se |
Elektronische Aufsätze |
| title_sort |
wandel der therapieergebnisse bei akuter leukämie unter anwendung verschiedener behandlungsschemata, mit besonderer berücksichtigung spezieller gnotobiotischer maßnahmen |
| title_auth |
Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen |
| abstract |
Summary 202 patients with acute leukemia (156 myeloid-AML, 46 lymphatic and undifferentiated-ALL/AUL) were studied retrospectively for the efficiency of different treatment schedules. Other variables we analysed were the influence of infection prevention with reverse isolation in laminar air flow units and of the age as a prognostic factor. 34% of all AML-patients achieved complete remission. Therapy with Adriamycin, Cytosine-Arabinoside and Vincristine resulted in 25 complete remissions in 51 patients (49%). The median duration of remission was 8 months and the median survival 19 months. The remission rate was improved by treatment with Cytosine-Arabinoside, 6-Thioguanine and Daunomycin (11 of 17 patients). Remission rate was significantly higher in patients up to 30 years of age than in patients older than 50 years (p<0.008). Survival and remission duration were not different in respect to the age. Reverse isolation with total enteral and topical decontamination resulted in a higher remission rate (p=0.06 not significant) in AML-patients, compared with the control-group. Survival lasted longer with infection prevention. In ALL/AUL-patients the rate of complete remissions was 16 of 34 patients (47%), with a median survival of 17 months. Patients up to the age of 30 had a higher remission rate than those older than 50 years (p=0.017). Patients with ALL/AUL younger than 31 years had a median duration of remission of 16 months and a survival probability of 0.66 after 43 months. |
| abstractGer |
Summary 202 patients with acute leukemia (156 myeloid-AML, 46 lymphatic and undifferentiated-ALL/AUL) were studied retrospectively for the efficiency of different treatment schedules. Other variables we analysed were the influence of infection prevention with reverse isolation in laminar air flow units and of the age as a prognostic factor. 34% of all AML-patients achieved complete remission. Therapy with Adriamycin, Cytosine-Arabinoside and Vincristine resulted in 25 complete remissions in 51 patients (49%). The median duration of remission was 8 months and the median survival 19 months. The remission rate was improved by treatment with Cytosine-Arabinoside, 6-Thioguanine and Daunomycin (11 of 17 patients). Remission rate was significantly higher in patients up to 30 years of age than in patients older than 50 years (p<0.008). Survival and remission duration were not different in respect to the age. Reverse isolation with total enteral and topical decontamination resulted in a higher remission rate (p=0.06 not significant) in AML-patients, compared with the control-group. Survival lasted longer with infection prevention. In ALL/AUL-patients the rate of complete remissions was 16 of 34 patients (47%), with a median survival of 17 months. Patients up to the age of 30 had a higher remission rate than those older than 50 years (p=0.017). Patients with ALL/AUL younger than 31 years had a median duration of remission of 16 months and a survival probability of 0.66 after 43 months. |
| abstract_unstemmed |
Summary 202 patients with acute leukemia (156 myeloid-AML, 46 lymphatic and undifferentiated-ALL/AUL) were studied retrospectively for the efficiency of different treatment schedules. Other variables we analysed were the influence of infection prevention with reverse isolation in laminar air flow units and of the age as a prognostic factor. 34% of all AML-patients achieved complete remission. Therapy with Adriamycin, Cytosine-Arabinoside and Vincristine resulted in 25 complete remissions in 51 patients (49%). The median duration of remission was 8 months and the median survival 19 months. The remission rate was improved by treatment with Cytosine-Arabinoside, 6-Thioguanine and Daunomycin (11 of 17 patients). Remission rate was significantly higher in patients up to 30 years of age than in patients older than 50 years (p<0.008). Survival and remission duration were not different in respect to the age. Reverse isolation with total enteral and topical decontamination resulted in a higher remission rate (p=0.06 not significant) in AML-patients, compared with the control-group. Survival lasted longer with infection prevention. In ALL/AUL-patients the rate of complete remissions was 16 of 34 patients (47%), with a median survival of 17 months. Patients up to the age of 30 had a higher remission rate than those older than 50 years (p=0.017). Patients with ALL/AUL younger than 31 years had a median duration of remission of 16 months and a survival probability of 0.66 after 43 months. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen |
| url |
http://dx.doi.org/10.1007/BF01485023 |
| remote_bool |
true |
| author2 |
Link, H. Frauer, H. M. Wilms, K. Waller, H. D. |
| author2Str |
Link, H. Frauer, H. M. Wilms, K. Waller, H. D. |
| ppnlink |
NLEJ188988254 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| up_date |
2024-07-05T23:53:00.372Z |
| _version_ |
1803785161011101696 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ199367191</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506103810.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1983 xx |||||o 00| ||ger c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ199367191</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Wandel der Therapieergebnisse bei akuter Leukämie unter Anwendung verschiedener Behandlungsschemata, mit besonderer Berücksichtigung spezieller gnotobiotischer Maßnahmen</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1983</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary 202 patients with acute leukemia (156 myeloid-AML, 46 lymphatic and undifferentiated-ALL/AUL) were studied retrospectively for the efficiency of different treatment schedules. Other variables we analysed were the influence of infection prevention with reverse isolation in laminar air flow units and of the age as a prognostic factor. 34% of all AML-patients achieved complete remission. Therapy with Adriamycin, Cytosine-Arabinoside and Vincristine resulted in 25 complete remissions in 51 patients (49%). The median duration of remission was 8 months and the median survival 19 months. The remission rate was improved by treatment with Cytosine-Arabinoside, 6-Thioguanine and Daunomycin (11 of 17 patients). Remission rate was significantly higher in patients up to 30 years of age than in patients older than 50 years (p<0.008). Survival and remission duration were not different in respect to the age. Reverse isolation with total enteral and topical decontamination resulted in a higher remission rate (p=0.06 not significant) in AML-patients, compared with the control-group. Survival lasted longer with infection prevention. In ALL/AUL-patients the rate of complete remissions was 16 of 34 patients (47%), with a median survival of 17 months. Patients up to the age of 30 had a higher remission rate than those older than 50 years (p=0.017). Patients with ALL/AUL younger than 31 years had a median duration of remission of 16 months and a survival probability of 0.66 after 43 months.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Link, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Frauer, H. M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilms, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Waller, H. D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Journal of molecular medicine</subfield><subfield code="d">1922</subfield><subfield code="g">61(1983) vom: Juli, Seite 329-338</subfield><subfield code="w">(DE-627)NLEJ188988254</subfield><subfield code="w">(DE-600)1462132-0</subfield><subfield code="x">1432-1440</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:61</subfield><subfield code="g">year:1983</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:329-338</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01485023</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">61</subfield><subfield code="j">1983</subfield><subfield code="c">7</subfield><subfield code="h">329-338</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| score |
7.399289 |